Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib first-line study in advanced hepatocellular carcinoma
ChiCTR2200061888Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Tangdu Hospital. Primary endpoint: Objective response rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200061888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061888.